Market Currents
Cowen says when you consider the potential of Threshold Pharmaceuticals (THLD -0.2%) pancreatic...
-
Friday, May 25, 2012, 3:24 PM ETCowen says when you consider the potential of Threshold Pharmaceuticals (THLD -0.2%) pancreatic cancer drug TH-302, the stock is definitely undervalued. The firm estimates the sales potential for the drug in the U.S. alone is close to $1.5B.
Other date
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles
